We are live on ! Find out more
FHTX icon

Foghorn Therapeutics
FHTX

60 hedge funds and large institutions have $357M invested in Foghorn Therapeutics in 2022 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 20 increasing their positions, 14 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

43% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 14

3.24% more ownership

Funds ownership: 60.13% → 63.36% (+3.2%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

2% less funds holding

Funds holding: 61 → 60 (-1)

6% less capital invested

Capital invested by funds: $379M → $357M (-$21.7M)

Holders
60
Holders Change
-1
Holders Change %
-1.64%
% of All Funds
1.01%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
12
Increased
20
Reduced
14
Closed
12
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
+$195K

Top Buyers

1
DM
Deerfield Management
New York
+$6.95M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.79M
3
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.07M
4
Morgan Stanley
Morgan Stanley
New York
+$2.49M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$1.89M

Top Sellers

1
Citadel Advisors
Citadel Advisors
Florida
-$892K
2
KCM
Kingdon Capital Management
New York
-$826K
3
N
Nuveen
North Carolina
-$687K
4
BlackRock
BlackRock
New York
-$425K
5
State of Wisconsin Investment Board
State of Wisconsin Investment Board
Wisconsin
-$396K
Name Holding Trade Value Shares
Change 		Change in
Stake
FP
1
Flagship Pioneering
Massachusetts
$172M – – –
Fidelity Investments
2
Fidelity Investments
Massachusetts
$46.7M +$3.07M +238,012 +7%
AG
3
Artal Group
Luxembourg
$23.4M – – –
EC
4
Euclidean Capital
New York
$17.2M – – –
Morgan Stanley
5
Morgan Stanley
New York
$16.6M +$2.49M +192,736 +19%
BlackRock
6
BlackRock
New York
$14.7M -$425K -32,960 -3%
Vanguard Group
7
Vanguard Group
Pennsylvania
$13.7M +$1.89M +146,819 +17%
DM
8
Deerfield Management
New York
$10.6M +$6.95M +538,660 +226%
AI
9
Alphabet Inc
California
$6.81M – – –
DCM
10
Driehaus Capital Management
Illinois
$5.21M +$812K +62,940 +20%
Point72 Asset Management
11
Point72 Asset Management
Connecticut
$5.11M +$4.79M +370,800 +7,131%
State Street
12
State Street
Massachusetts
$5.03M +$669K +51,807 +16%
Geode Capital Management
13
Geode Capital Management
Massachusetts
$4.85M +$81.6K +6,323 +2%
BC
14
Birchview Capital
Vermont
$3.87M -$120K -9,300 -3%
Northern Trust
15
Northern Trust
Illinois
$2.54M +$239K +18,536 +11%
Millennium Management
16
Millennium Management
New York
$1.89M -$303K -23,505 -14%
N
17
Nuveen
North Carolina
$811K -$687K -53,270 -47%
Charles Schwab
18
Charles Schwab
California
$723K +$16.2K +1,257 +2%
Bank of New York Mellon
19
Bank of New York Mellon
New York
$693K -$131K -10,130 -17%
BBA
20
Baker Bros. Advisors
New York
$612K – – –
RJA
21
Raymond James & Associates
Florida
$383K +$25.8K +2,000 +8%
RhumbLine Advisers
22
RhumbLine Advisers
Massachusetts
$314K +$5.17K +401 +2%
DTL
23
Dynamic Technology Lab
Singapore
$279K +$265K +20,551 New
HF
24
HRT Financial
New York
$240K +$228K +17,651 New
Goldman Sachs
25
Goldman Sachs
New York
$223K +$41.7K +3,233 +25%
1
2 3

FHTX Hedge Fund Activity: Q2 2022 in Review

60 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q2 2022, worth a combined $357M — down 5.7% from $379M a quarter earlier.

Fund positioning in FHTX was balanced in Q2 2022: 12 funds opened new positions, 12 closed out, 20 added to existing stakes and 14 trimmed.

The largest buyer was Deerfield Management, adding an estimated $6.95M. The largest seller was Citadel Advisors, exiting entirely with an estimated $892K sold.

  • 60 institutional investors held Foghorn Therapeutics (FHTX) as of Q2 2022, down from 61 in Q1 2022.
  • Funds reported $357M of Foghorn Therapeutics stock for Q2 2022, down 5.7% quarter-over-quarter.
  • 12 funds opened new Foghorn Therapeutics positions in Q2 2022 and 12 closed out, a net change of 0 holders.
  • The largest Foghorn Therapeutics buyer in Q2 2022 was Deerfield Management, an estimated $6.95M added.
  • The largest Foghorn Therapeutics seller in Q2 2022 was Citadel Advisors, an estimated $892K sold.

Based on aggregated 13F filings for Q2 2022.